GO
Loading...

Celgene Corp

More

  • LOS ANGELES, Dec 23- Express Scripts, the largest manager of prescription drug plans for U.S. employers, is taking an increasingly aggressive stance in price negotiations with pharmaceutical companies after winning discounts on medications with a strategy introduced last year. On Monday, Express Scripts said it lined up a cheaper price for AbbVie Inc's newly...

  • Dec 22- The largest U.S. pharmacy benefit manager said on Monday it has lined up a cheaper price for AbbVie Inc's newly approved hepatitis C treatment and, in most cases, will no longer cover Gilead Sciences Inc's treatments after trying for nearly a year to win a deeper discount. Express Scripts' move reignited investor concerns that pharmaceutical companies...

  • Cramer’s perfect recipe for a Santa Claus rally Thursday, 18 Dec 2014 | 6:13 PM ET
    Traders work on the floor of the New York Stock Exchange.

    Jim Cramer is seeing some good signs in the economy right now. Could they be the perfect ingredients for a Santa Claus rally?

  • Lightning Round: Good stock with a good yield Wednesday, 17 Dec 2014 | 6:57 PM ET

    Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Cramer Remix: With oil going down, sell this asap Wednesday, 10 Dec 2014 | 7:01 PM ET

    It’s a popular yield play, but the tables have turned due to low oil prices."Mad Money" host Jim Cramer thinks it needs to be sold immediately.

  • Cramer’s biotech bonanza: A zone free from oil pain Wednesday, 10 Dec 2014 | 6:33 PM ET

    Jim Cramer has spotted one sector that keeps going higher, even as oil goes lower. Get 'em while they're hot!

  • This data represents a "quantum leap" in the management of this disorder by shifting from "life-long symptom management to once-and-done cures," Roth Capital Partner's Debjit Chattopadhyay said, raising his price target on the stock to $90 from $50. LentiGlobin's results read-through favorably to the sickle-cell indication, Piper Jaffray analysts said,...

  • ASH: The Celgene show, this time through partners Monday, 8 Dec 2014 | 1:33 PM ET

    Celgene's partnering strategy, which has accelerated in recent years, is starting to bear fruit; many of the most-watched stocks out of ASH fall under its umbrella.

  • Midday movers: McDonald's, Sony, Celgene & more Monday, 8 Dec 2014 | 1:12 PM ET

    Some of Monday's midday movers:

  • Celgene CEO: Cancer drug pipeline booming  Monday, 8 Dec 2014 | 12:37 PM ET

    CNBC's Meg Tirrell speaks to Robert Hugin, Celgene chairman & CEO, about exciting new drugs emerging from Celgene's pipeline and the progress being made with Multiple myeloma.

  • Lightning Round: Time to buy buy buy for 2015 Thursday, 4 Dec 2014 | 6:50 PM ET

    Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Cramer’s big discovery under the market's hood Wednesday, 3 Dec 2014 | 6:16 PM ET

    Jim Cramer takes a close look under the market's hood and makes a big discovery that could impact your portfolio.

  • Cramer's heated love affair with biotech Tuesday, 2 Dec 2014 | 6:33 PM ET
    File photo: Michael LeClair, left, and Kevin Fleurimond, in the manufacturing room of Biogen Idec.

    As the global economy faces headwinds each day, Jim Cramer knows this group can withstand stormy weather more often than the rest.

  • Teva Pharma names Peterburg new chairman Wednesday, 26 Nov 2014 | 1:39 PM ET

    Nov 26- The board of Teva Pharmaceutical Industries Ltd elected Yitzhak Peterburg as its chairman, succeeding Phillip Frost, who is due to step down at the end of the year. The company also appointed Sol Barer, the former chief executive of Celgene Corp, as a director. Teva stock was up 0.8 percent at $57.02 on the New York Stock Exchange.

  • Actavis Plc, Gilead Sciences, Celgene and other biotech names were among the S&P 500' s biggest drivers, a day after Allergan agreed to be bought by Actavis. The S&P health care index was up 1.6 percent, while shares of Actavis were up 8.3 percent, Gilead's rose 3.3 percent and shares of Celgene were up 2.4 percent. Helping Actavis were bullish analyst notes.

  • US STOCKS-S&P 500 hits record, healthcare leads gains Tuesday, 18 Nov 2014 | 1:45 PM ET

    Actavis Plc, Gilead, Celgene and other biotech names were among the S&P 500' s biggest drivers, a day after Allergan agreed to be bought by Actavis. The S&P health care index was up 1.4 percent, while shares of Actavis were up 7.7 percent, Gilead's rose 2.9 percent and shares of Celgene were up 2.4 percent. Helping Actavis were bullish analyst notes.

  • Midday movers: FibroGen, Google, McDonald's & more Friday, 14 Nov 2014 | 1:12 PM ET

    Some of Friday's midday movers:

  • Cramer spotlight: These three sectors keep growing Tuesday, 11 Nov 2014 | 6:05 PM ET
    Traders on the floor of the New York Stock Exchange.

    Think that the market was uneventful on Tuesday? Not so fast, Jim Cramer sees these three sectors growing fast, which could lead to profits.

  • Cramer's military salute: Long-term investing keys Monday, 10 Nov 2014 | 6:10 PM ET

    Jim Cramer focuses on three long-term investment themes specialized for veterans and active-duty soldiers.

  • Lightning Round: Celgene, Sysco & more Monday, 3 Nov 2014 | 7:51 PM ET

    Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.